ClinicalTrials.gg
CompletedNCT00623428Updated Jul 22, 2013Results posted

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

A Phase 3 interventional study of peginterferon alfa-2a and Ribavirin in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 101 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-22.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
235
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.

Enrollment
28th of 83
235 · median 129
Started
2008
with 3 others
Phase 3
19 of 83
none open now
Registered
40th of 83
by date
Lead sponsor
35 of 83
Hoffmann-La Roche

Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 28th largest by enrollment, is one of 4 that started in 2008, is one of 19 in phase 3, and was the 40th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic as a file.
02

Study summary

This study will evaluate the efficacy and safety of peginterferon alfa-2a 40KD + ribavirin combination therapy given for 24 weeks versus 48 weeks in patients with chronic hepatitis C, genotype 2/3.

Read the detailed description

During a pre-study run-in phase patients with chronic hepatitis C genotype 2/3, who had started therapy with PEG-IFN alfa-2a plus ribavirin according to local standard of care and did not achieve a rapid viral response (RVR) (defined as Hepatitis C virus (HCV) RNA \<15 IU/mL at Week 4 of treatment measured with the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test) were eligible for the study and entered the screening phase between treatment Week 4 and 8 as soon as the result of the Week 4 HCV RNA test was available.

Eligible patients entered the study and continued with the dose regimens of PEG-IFN alfa-2a and ribavirin they were taking prior to enrolment into the trial up to Week 24 of treatment. Patients who achieved at least a 2-log10 drop of HCV RNA at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA \<15 IU/mL, and who were still taking study medication at treatment Week 24, were randomized at treatment Week 24 to one of the two study groups. Upon randomization, participants either stopped treatment (equaling 24 weeks of treatment) or continued treatment for another 24 weeks (equaling 48 weeks of treatment). A treatment free follow-up period of 24 weeks (for participants in the 48-week treatment group) or 48 weeks (participants in the 24-week treatment group) completed the study.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • serological evidence of chronic (CHC);
  • CHC genotype 2 or 3;
  • receiving PEGASYS + Copegus according to local standard of care and no rapid viral response (RVR);
  • compensated liver disease.

Exclusion criteria

Exclusion Criteria:

  • pegylated interferon, standard interferon or ribavirin therapy at any time prior to initiation of current therapy with PEGASYS + Copegus;
  • coinfection with hepatitis A or B, or (HIV);
  • history or other evidence of decompensated liver disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
235 participants (actual)

Study arms

  • Experimental
    PEG-IFN alfa-2a + Ribavirin for 24 weeks

    After 24 weeks of treatment with pegylated interferon alfa-2a (PEG-IFN alfa-2a) 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA \<15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, at which time treatment was stopped. Participants were followed for an additional 48 weeks during the treatment-free follow-up period.

    Drug: peginterferon alfa-2a · Drug: Ribavirin

  • Active comparator
    PEG-IFN alfa-2a + Ribavirin for 48 weeks

    After 24 weeks of treatment with PEG-IFN alfa-2a 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of HCV RNA at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA \<15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, and continued treatment for another 24 weeks (for a total of 48 weeks of treatment). Participants were followed for an additional 24 weeks during the treatment-free follow-up period.

    Drug: peginterferon alfa-2a · Drug: Ribavirin

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Sustained Virologic Response 24 Weeks After Scheduled Completion of Treatment

    Sustained virological response (SVR) is defined as a single last HCV RNA measurement \<15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) 24 weeks after scheduled treatment completion, defined as Week 44 or later for participants randomized to the 24-week treatment period or Week 68 or later for participants randomized to the 48-week treatment period. Participants without measurements at the end of the 24-week untreated follow-up period were considered non-responders in the analysis.

    Time frame: 24 weeks after scheduled treatment completion (approximately Week 48 for participants in the 24-week treatment group and Week 72 for participants in the 48-week treatment group.

  2. Percentage of Participants With a Sustained Virologic Response 24 Weeks After Actual End of Treatment

    Sustained virological response (SVR) is defined as a single last HCV RNA measurement \<15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) at 24 weeks after actual end of study treatment. For participants in the 48-week treatment group who stopped study treatment prior to Week 48 for any reason, the HCV RNA measurements 24 weeks after actual end of treatment were used in the analysis. Participants without a 24-week post treatment measurement are considered non-responders.

    Time frame: 24 weeks after actual end of treatment (range from Week 48 to Week 72).

Secondary outcomes

  1. Percentage of Participants With Virological Response 72 Weeks After Treatment Initiation

    Virological response 72 weeks after treatment initiation is defined as the percentage of participants with HCV RNA \<15 IU/mL as measured by the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test at 48 weeks post completion of the 24 week treatment period and 24 weeks post completion of the 48 week treatment period. Participants without Week 72 measurements were considered non-responders in the analysis.

    Time frame: Week 72

  2. Percentage of Participants With Virological Response at End of Treatment

    Virological response at the end of treatment was defined as the percentage of participants with HCV RNA \<15 IU/mL as measured by the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test after the last dose of study medication.

    Time frame: End of Treatment (Week 24 and Week 48 for each treatment group respectively).

  3. Percentage of Participants With Virological Relapse

    Virological relapse defined as the percentage of participants with a virological response at end of treatment but who did not have a sustained virological response 24 weeks after the end of treatment. Virological response at end of treatment is defined as a single last HCV RNA measurement \<15 IU/ml measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test at the day of last dose of study medication. Sustained virological response 24 weeks after the actual treatment end (SVR24) is defined as a single last HCV RNA measurement \<15 IU/ml at least 20 weeks after treatment end.

    Time frame: End of treatment (Weeks 24 or 48) and 24 weeks after the end of treatment (weeks 48 and 72 in each treatment group respectively).

  4. Percentage of Participants With a Sustained Virologic Response 12 Weeks After Actual End of Treatment

    Sustained virological response (SVR) is defined as a single last HCV RNA measurement \<15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) at 12 weeks after actual end of study treatment. For participants in the 48-week treatment group who stopped study treatment prior to Week 48 for any reason, the HCV RNA measurements 12 weeks after actual end of treatment were used in the analysis. Participants without a 12-week post treatment measurement are considered non-responders.

    Time frame: 12 weeks after actual end of treatment (range from Week 36 to Week 60)

  5. Number of Participants With Adverse Events (AEs)

    An AE was defined as a sign or symptom, including intercurrent illness, that occurred during the course of the clinical study after treatment had started. A related AE is an event assessed by the Investigator to be remotely, possibly, or probably related to study treatment according to criteria provided in the protocol. A severe AE was an event graded by the Investigator as "incapacitating with inability to work or perform normal daily activity". A serious AE (SAE) was defined as any experience that suggests a significant hazard, contraindication, side effect or precaution. This includes any experience which was fatal; was life-threatening; required inpatient hospitalization or prolongation of an existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/ birth defect; was medically significant or required intervention to prevent one or other of the outcomes listed above.

    Time frame: From Week 1 through Week 72.

07

Results

Posted Jun 24, 2013

Participant flow

Patients with Chronic Hepatitis C, Genotype 2 or 3 who had started therapy with PEG-IFN alfa-2a plus ribavirin according to local standard of care during a pre-study run-in phase and did not achieve a rapid viral response defined as HCV RNA \<15 IU/mL at Week 4 of treatment were eligible and entered the screening phase between treatment Weeks 4-8.

Treatment Period
Participant flow — Treatment Period
MilestonePEG-IFN Alfa-2a + Ribavirin for 24 WeeksPEG-IFN Alfa-2a + Ribavirin for 48 Weeks
Started9593
Completed9566
Not completed027
Withdrew: Adverse event/intercurrent illness09
Withdrew: Death01
Withdrew: Did not cooperate / refused treatment013
Withdrew: Insufficient therapeutic response02
Withdrew: Other01
Withdrew: Withdrawal by subject01
Follow-up Period
Participant flow — Follow-up Period
MilestonePEG-IFN Alfa-2a + Ribavirin for 24 WeeksPEG-IFN Alfa-2a + Ribavirin for 48 Weeks
Started9593
Completed6678
Not completed2915
Withdrew: Relapse post-treatment113
Withdrew: Failure to return102
Withdrew: Patient withdrew consent54
Withdrew: Hcv-rna detectable at end of treatment21
Withdrew: Did not cooperate03
Withdrew: Reason not specified11
Withdrew: Death01

Outcome measures

PrimaryPercentage of Participants With a Sustained Virologic Response 24 Weeks After Scheduled Completion of Treatment

Sustained virological response (SVR) is defined as a single last HCV RNA measurement \<15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) 24 weeks after scheduled treatment completion, defined as Week 44 or later for participants randomized to the 24-week treatment period or Week 68 or later for participants randomized to the 48-week treatment period. Participants without measurements at the end of the 24-week untreated follow-up period were considered non-responders in the analysis.

Time frame:
24 weeks after scheduled treatment completion (approximately Week 48 for participants in the 24-week treatment group and Week 72 for participants in the 48-week treatment group.
Reported as:
Number · percentage of participants
Percentage of Participants With a Sustained Virologic Response 24 Weeks After Scheduled Completion of Treatment
percentage of participantsPEG-IFN Alfa-2a + Ribavirin for 24 WeeksPEG-IFN Alfa-2a + Ribavirin for 48 Weeks
Percentage of Participants With a Sustained Virologic Response 24 Weeks After Scheduled Completion of Treatment5257
Statistical analysis
  • PEG-IFN Alfa-2a + Ribavirin for 24 Weeks vs PEG-IFN Alfa-2a + Ribavirin for 48 Weeks · Cochran-Mantel-Haenszel · p = 0.4557 · Odds ratio (or): 0.80 · 95% CI 0.45 to 1.43The odds ratio is the ratio of the odds of a response in the 24-week treatment group to the odds of a response in the 48-week treatment group. (second column).
SecondaryPercentage of Participants With Virological Response 72 Weeks After Treatment Initiation

Virological response 72 weeks after treatment initiation is defined as the percentage of participants with HCV RNA \<15 IU/mL as measured by the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test at 48 weeks post completion of the 24 week treatment period and 24 weeks post completion of the 48 week treatment period. Participants without Week 72 measurements were considered non-responders in the analysis.

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With Virological Response 72 Weeks After Treatment Initiation
percentage of participantsPEG-IFN Alfa-2a + Ribavirin for 24 WeeksPEG-IFN Alfa-2a + Ribavirin for 48 Weeks
Percentage of Participants With Virological Response 72 Weeks After Treatment Initiation4457
Statistical analysis
  • PEG-IFN Alfa-2a + Ribavirin for 24 Weeks vs PEG-IFN Alfa-2a + Ribavirin for 48 Weeks · Cochran-Mantel-Haenszel · p = 0.0788 · Odds ratio (or): 0.59 · 95% CI 0.33 to 1.06The odds ratio is the ratio of the odds of a response in the 24-week treatment group to the odds of a response in the 48-week treatment group.
SecondaryPercentage of Participants With Virological Response at End of Treatment

Virological response at the end of treatment was defined as the percentage of participants with HCV RNA \<15 IU/mL as measured by the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test after the last dose of study medication.

Time frame:
End of Treatment (Week 24 and Week 48 for each treatment group respectively).
Reported as:
Number · percentage of participants
Percentage of Participants With Virological Response at End of Treatment
percentage of participantsPEG-IFN Alfa-2a + Ribavirin for 24 WeeksPEG-IFN Alfa-2a + Ribavirin for 48 Weeks
Percentage of Participants With Virological Response at End of Treatment9390
Statistical analysis
  • PEG-IFN Alfa-2a + Ribavirin for 24 Weeks vs PEG-IFN Alfa-2a + Ribavirin for 48 Weeks · Cochran-Mantel-Haenszel · p = 0.5654 · Odds ratio (or): 1.36 · 95% CI 0.48 to 3.87The odds ratio is the ratio of the odds of a response in the 24-week treatment group to the odds of a response in the 48-week treatment group.
SecondaryPercentage of Participants With Virological Relapse

Virological relapse defined as the percentage of participants with a virological response at end of treatment but who did not have a sustained virological response 24 weeks after the end of treatment. Virological response at end of treatment is defined as a single last HCV RNA measurement \<15 IU/ml measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test at the day of last dose of study medication. Sustained virological response 24 weeks after the actual treatment end (SVR24) is defined as a single last HCV RNA measurement \<15 IU/ml at least 20 weeks after treatment end.

Time frame:
End of treatment (Weeks 24 or 48) and 24 weeks after the end of treatment (weeks 48 and 72 in each treatment group respectively).
Reported as:
Number · percentage of participants
Percentage of Participants With Virological Relapse
percentage of participantsPEG-IFN Alfa-2a + Ribavirin for 24 WeeksPEG-IFN Alfa-2a + Ribavirin for 48 Weeks
Percentage of Participants With Virological Relapse4129
PrimaryPercentage of Participants With a Sustained Virologic Response 24 Weeks After Actual End of Treatment

Sustained virological response (SVR) is defined as a single last HCV RNA measurement \<15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) at 24 weeks after actual end of study treatment. For participants in the 48-week treatment group who stopped study treatment prior to Week 48 for any reason, the HCV RNA measurements 24 weeks after actual end of treatment were used in the analysis. Participants without a 24-week post treatment measurement are considered non-responders.

Time frame:
24 weeks after actual end of treatment (range from Week 48 to Week 72).
Reported as:
Number · percentage of participants
Percentage of Participants With a Sustained Virologic Response 24 Weeks After Actual End of Treatment
percentage of participantsPEG-IFN Alfa-2a + Ribavirin for 24 WeeksPEG-IFN Alfa-2a + Ribavirin for 48 Weeks
Percentage of Participants With a Sustained Virologic Response 24 Weeks After Actual End of Treatment5261
Statistical analysis
  • PEG-IFN Alfa-2a + Ribavirin for 24 Weeks vs PEG-IFN Alfa-2a + Ribavirin for 48 Weeks · Cochran-Mantel-Haenszel · p = 0.1934 · Odds ratio (or): 0.68 · 95% CI 0.38 to 1.21The odds ratio is the ratio of the odds of a response in the 24-week treatment group to the odds of a response in the 48-week treatment group.
SecondaryPercentage of Participants With a Sustained Virologic Response 12 Weeks After Actual End of Treatment

Sustained virological response (SVR) is defined as a single last HCV RNA measurement \<15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) at 12 weeks after actual end of study treatment. For participants in the 48-week treatment group who stopped study treatment prior to Week 48 for any reason, the HCV RNA measurements 12 weeks after actual end of treatment were used in the analysis. Participants without a 12-week post treatment measurement are considered non-responders.

Time frame:
12 weeks after actual end of treatment (range from Week 36 to Week 60)
Reported as:
Number · percentage of participants
Percentage of Participants With a Sustained Virologic Response 12 Weeks After Actual End of Treatment
percentage of participantsPEG-IFN Alfa-2a + Ribavirin for 24 WeeksPEG-IFN Alfa-2a + Ribavirin for 48 Weeks
Percentage of Participants With a Sustained Virologic Response 12 Weeks After Actual End of Treatment5261
Statistical analysis
  • PEG-IFN Alfa-2a + Ribavirin for 24 Weeks vs PEG-IFN Alfa-2a + Ribavirin for 48 Weeks · Cochran-Mantel-Haenszel · p = 0.1934 · Odds ratio (or): 0.68 · 95% CI 0.38 to 1.21The odds ratio is the ratio of the odds of a response in the 24-week treatment group to the odds of a response in the 48-week treatment group.
SecondaryNumber of Participants With Adverse Events (AEs)

An AE was defined as a sign or symptom, including intercurrent illness, that occurred during the course of the clinical study after treatment had started. A related AE is an event assessed by the Investigator to be remotely, possibly, or probably related to study treatment according to criteria provided in the protocol. A severe AE was an event graded by the Investigator as "incapacitating with inability to work or perform normal daily activity". A serious AE (SAE) was defined as any experience that suggests a significant hazard, contraindication, side effect or precaution. This includes any experience which was fatal; was life-threatening; required inpatient hospitalization or prolongation of an existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/ birth defect; was medically significant or required intervention to prevent one or other of the outcomes listed above.

Time frame:
From Week 1 through Week 72.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsPEG-IFN Alfa-2a + Ribavirin for 24 WeeksPEG-IFN Alfa-2a + Ribavirin for 48 Weeks
Any AE8188
Severe AE1324
AE related to PEG-IFN alfa-2a7886
AE related to ribavirin7283
Serious AE411
SAE related to PEG-IFN alfa-2a07
SAE related to ribavirin04
Deaths01

Adverse events

Collected over 72 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEG-IFN Alfa-2a + Ribavirin for 24 Weeks—4/95 (4.2%)81/95 (85.3%)
PEG-IFN Alfa-2a + Ribavirin for 48 Weeks—11/93 (11.8%)87/93 (93.5%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventPEG-IFN Alfa-2a + Ribavirin for 24 WeeksPEG-IFN Alfa-2a + Ribavirin for 48 Weeks
Psychotic disorderPsychiatric disorders0/951/93
DepressionPsychiatric disorders0/951/93
AnaemiaBlood and lymphatic system disorders1/951/93
ThrombocytopeniaBlood and lymphatic system disorders0/951/93
Rectal haemorrhageGastrointestinal disorders0/951/93
VomitingGastrointestinal disorders0/951/93
CellulitisInfections and infestations0/951/93
SepsisInfections and infestations0/951/93
Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/951/93
Cerebrovascular accidentNervous system disorders0/951/93
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPEG-IFN Alfa-2a + Ribavirin for 24 WeeksPEG-IFN Alfa-2a + Ribavirin for 48 Weeks
FatigueGeneral disorders33/9547/93
HeadacheNervous system disorders17/9530/93
NauseaGastrointestinal disorders13/9524/93
InsomniaPsychiatric disorders21/9521/93
PruritusSkin and subcutaneous tissue disorders17/9520/93
MyalgiaMusculoskeletal and connective tissue disorders8/9518/93
AstheniaGeneral disorders18/9514/93
AlopeciaSkin and subcutaneous tissue disorders15/9517/93
Decreased appetiteMetabolism and nutrition disorders8/9515/93
Dry skinSkin and subcutaneous tissue disorders13/9514/93

Baseline characteristics

Age Continuous
Age Continuous(years)PEG-IFN Alfa-2a + Ribavirin for 24 WeeksPEG-IFN Alfa-2a + Ribavirin for 48 WeeksTotal
Mean48.8 ± 9.8348.6 ± 10.1248.7 ± 9.95
Age, Customized
Age, Customized(participants)PEG-IFN Alfa-2a + Ribavirin for 24 WeeksPEG-IFN Alfa-2a + Ribavirin for 48 WeeksTotal
≤ 50 years4753100
> 50 years484088
Sex: Female, Male
Sex: Female, Male(Participants)PEG-IFN Alfa-2a + Ribavirin for 24 WeeksPEG-IFN Alfa-2a + Ribavirin for 48 WeeksTotal
Female403979
Male5554109
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PEG-IFN Alfa-2a + Ribavirin for 24 WeeksPEG-IFN Alfa-2a + Ribavirin for 48 WeeksTotal
Caucasian or white8281163
Black8614
Asian or oriental123
Other448
Hepatitis C virus (HCV) genotype
Hepatitis C virus (HCV) genotype(participants)PEG-IFN Alfa-2a + Ribavirin for 24 WeeksPEG-IFN Alfa-2a + Ribavirin for 48 WeeksTotal
HCV Genotype 2191938
HCV Genotype 37674150
Pre-treatment HCV ribonucleic acid (RNA)
Pre-treatment HCV ribonucleic acid (RNA)(log10 IU/mL)PEG-IFN Alfa-2a + Ribavirin for 24 WeeksPEG-IFN Alfa-2a + Ribavirin for 48 WeeksTotal
Mean6.11 ± 0.6246.17 ± 0.7736.14 ± 0.700
Region
Region(participants)PEG-IFN Alfa-2a + Ribavirin for 24 WeeksPEG-IFN Alfa-2a + Ribavirin for 48 WeeksTotal
Non-U.S.8582167
U.S.101121
08

Study locations

101 sites
  • Birmingham, Alabama 35294, United States
  • La Jolla, California 92037-1030, United States
  • Lancaster, California 93534, United States
  • Long Beach, California 90822, United States
  • Los Angeles, California 90048, United States
  • Los Angeles, California 90057, United States
  • Sacramento, California 95816, United States
  • Sacramento, California 95817, United States
  • San Diego, California 92103-8465, United States
  • Torrance, California 90505, United States
  • Aurora, Colorado 80045, United States
  • Jacksonville, Florida 32256, United States
  • Orlando, Florida 32803, United States
  • Atlanta, Georgia 30308, United States
  • Marietta, Georgia 30060, United States
  • Honolulu, Hawaii 96813, United States
  • Baton Rouge, Louisiana 70890, United States
  • Opelousas, Louisiana 70520, United States
  • Boston, Massachusetts 02114, United States
  • Tupelo, Mississippi 38801, United States
  • St Louis, Missouri 63104, United States
  • St Louis, Missouri 63110, United States
  • Egg Harbour Township, New Jersey 08234, United States
  • Hackensack, New Jersey 07601, United States
  • Albuquerque, New Mexico 87131, United States
  • New York, New York 10016, United States
  • Syracuse, New York 13210, United States
  • Asheville, North Carolina 28801, United States
  • Chapel Hill, North Carolina 27599-7080, United States
  • Winston-salem, North Carolina 27103, United States
  • Oklahoma City, Oklahoma 73112-4481, United States
  • Portland, Oregon 97239, United States
  • Kingsport, Tennessee 37660, United States
  • Fort Sam Houston, Texas 78234-3879, United States
  • Salt Lake City, Utah 84132, United States
  • Charlottesville, Virginia 22908, United States
  • Fairfax, Virginia 22031, United States
  • Richmond, Virginia 23249, United States
  • Darlinghurst, 2010, Australia
  • Fremantle, 6160, Australia
  • Melbourne, 3186, Australia
  • Nedlands, 6009, Australia
  • Sydney, 2139, Australia
  • Graz, 8036, Austria
  • Innsbruck, 6020, Austria
  • Linz, 4010, Austria
  • Oberndorf, 5110, Austria
  • Wien, 1090, Austria
  • Wien, 1160, Austria
  • Antwerpen, 2650, Belgium
  • Bruxelles, 1000, Belgium
  • Bruxelles, 1020, Belgium
  • Bruxelles, 1070, Belgium
  • Gent, 9000, Belgium
  • Kortrijk, 8500, Belgium
  • Liege, 4000, Belgium
  • Brasilia, 70335-000, Brazil
  • Campinas, 13012-970, Brazil
  • Campinas, 13081-970, Brazil
  • Porto Alegre, 90020-090, Brazil
  • Porto Alegre, 90035-003, Brazil
  • Ribeirao Preto, 14049-900, Brazil
  • Rio de Janeiro, 20020-022, Brazil
  • Santo Andre, 09060-650, Brazil
  • Sao Luis, 78048-790, Brazil
  • Sao Paulo, 04040-003, Brazil
  • Sorocaba, 18047-600, Brazil
  • Vitoria, 29043-260, Brazil
  • Edmonton, Alberta T6G 2B7, Canada
  • Vancouver, British Columbia V6Z 2K5, Canada
  • Hamilton, Ontario L8N 4A6, Canada
  • Mississauga, Ontario L5M 4N4, Canada
  • Berlin, 10969, Germany
  • Berlin, 13353, Germany
  • Bonn, 53127, Germany
  • Düsseldorf, 40225, Germany
  • Düsseldorf, 40237, Germany
  • Frankfurt Am Main, 60590, Germany
  • Freiburg, 79106, Germany
  • Giessen, 35392, Germany
  • Hamburg, 20099, Germany
  • Heidelberg, 69120, Germany
  • Jena, 07747, Germany
  • Kiel, 24105, Germany
  • Köln, 50937, Germany
  • Mainz, 55101, Germany
  • München, 81675, Germany
  • Offenburg, 77654, Germany
  • Tübingen, 72076, Germany
  • ULM, 89081, Germany
  • Guadalajara, 44160, Mexico
  • Guadalajara, 44670, Mexico
  • Mexicali, 21000, Mexico
  • Mexico City, 14050, Mexico
  • Mexico Df, 11649, Mexico
  • Puebla, 72560, Mexico
  • Santurce, 00909, Puerto Rico
  • Lausanne, 1005, Switzerland
  • Lugano, 6903, Switzerland
  • St. Gallen, 9007, Switzerland

Showing the first 100 of 101 sites across 10 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2008
First posted
Feb 26, 2008
Start
Jun 2008
Primary completionActual
May 2012
CompletionActual
May 2012
Results first posted
Jun 24, 2013
Last update
Jul 22, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00623428
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 26, 2008
Start date
Jun 2008
Primary completion
May 2012
Completion
May 2012
Results posted
Jun 24, 2013
Last update
Jul 22, 2013

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin

Start the discussion